We are the combination of four hospitals: the General Hospital, the Children’s Hospital, the Women’s Hospital and the Traumatology, Rehabilitation and Burns Hospital. We are part of the Vall d’Hebron Barcelona Hospital Campus: a world-leading health park where healthcare plays a crucial role.
Patients are the centre and the core of our system. We are professionals committed to quality care and our organizational structure breaks down the traditional boundaries between departments and professional groups, with an exclusive model of knowledge areas.
Would you like to know what your stay at Vall d'Hebron will be like? Here you will find all the information.
The commitment of Vall d'Hebron University Hospital to innovation allows us to be at the forefront of medicine, providing first class care adapted to the changing needs of each patient.
Dr. Yenan Bryceson, Center for Hematology and Regenerative Medicine. Department of Medicine, Karolinska Institutet. Karolinska University Hospital - Stockholm- Sweden
"Hemophagocytic Lymphohistiocytosis: signaling processes and activation of cytotoxic lymphocytes and NK"
Defects in lymphocyte cytotoxicity are a cause of the life-threatening, early-onset hyperinflammatory syndrome hemophagocytic lymphohistiocytosis (HLH). Autosomal recessive mutations in PRF1, UNC13D, STXBP2, and STX11 have been associated with familial forms of HLH and disrupt lymphocyte-mediated target cell killing. A variety of other genetic mutations have also been associated with predisposition to HLH. I will review the molecular mechanism of lymphocyte cytotoxicity and efficacy of cellular assays for the diagnosis of patients. Moreover, the cellular basis of disease in different genetic forms of HLH will be discussed.
CV. Yenan Bryceson received his his PhD from Karolinska Institutet in 2008 after working in the lab of Eric Long at the NIH, and is currently Assistant Professor at the Center for Infectious Medicine at Karolinska University. His lab studies the molecular mechanisms of cytotoxic lymphocyte differentiation and function in the context of primary immunodeficiencies, hematological malignancies and systemic onset autoimmunity. The goal is to develop better diagnostic procedures and treatments for patients suffering rare genetic diseases, while providing further understanding of the human immune system that may also benefit the therapy of common diseases caused by dysregulated immunity. Yenan’s is recipient of an ERC starting grant and was recently named Wallenberg Academy Fellow. In his spare time he enjoys hiking, skiing, fly fishing and is trying to figure out surfing.
Host: Diagnostic Immunology Group, mmartinez@vhebron.net
The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”. Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health). Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information. Legal basis: Consent of the data subject. Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen. Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time. Source: The data subject. Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.